1601552-74-2

Upstream product

• 51803-78-2 nimesulide 
• 106-96-7 propargyl bromide 

Downstream Products

• 1601552-65-1 N-((1-((2-chloro-6-methoxyquinolin-3-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)-N-(2,2,4-trimethyl-7-phenoxy-1,2-dihydroquinolin-6-yl)methanesulfonamide 
• 1601552-66-2 N-((1-((2-chloro-6-methylquinolin-3-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)-N-(2,2,4-trimethyl-7-phenoxy-1,2-dihydroquinolin-6-yl)methanesulfonamide 
• 1601552-67-3 N-((1-((2-chloroquinolin-3-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)-N-(2,2,4-trimethyl-7-phenoxy-1,2-dihydroquinolin-6-yl)methanesulfonamide 
• 1601552-68-4 N-((1-((2-chloro-7-methylquinolin-3-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)-N-(2,2,4-trimethyl-7-phenoxy-1,2-dihydroquinolin-6-yl)methanesulfonamide 
• 1601552-69-5 N-phenyl-2-(4-((N-(2,2,4-trimethyl-7-phenoxy-1,2-dihydroquinolin-6-yl)methanesulfonamido)methyl)-1H-1,2,3-triazol-1-yl)acetamide 
• 1601552-70-8 N-(p-tolyl)-2-(4-((N-(2,2,4-trimethyl-7-phenoxy-1,2-dihydroquinolin-6-yl)methanesulfonamido)methyl)-1H-1,2,3-triazol-1-yl)acetamide 
• 1601552-71-9 N-(m-tolyl)-2-(4-{[N-(2,2,4-trimethyl-7-phenoxy-1,2-dihydroquinolin-6-yl)methanesulfonamido]methyl}-1H-1,2,3-triazol-1-yl)acetamide 
• 1601552-72-0 N-(4-methoxyphenyl)-2-(4-((N-(2,2,4-trimethyl-7-phenoxy-1,2-dihydroquinolin-6-yl)methanesulfonamido)methyl)-1H-1,2,3-triazol-1-yl)acetamide 
• 1601552-73-1 N-(4-methanesulfonamido-3-phenoxyphenyl)-2-(4-{[N-(2,2,4-trimethyl-7-phenoxy-1,2-dihydroquinolin-6-yl)methanesulfonamido]methyl}-1H-1,2,3-triazol-1-yl)acetamide 
• 1601552-75-3 C₂₂H₂₄N₂O₃S 

Relevant academic research and scientific papers

Synthesis of 2,2,4-trimethyl-1,2-dihydroquinolinyl substituted 1,2,3-triazole derivatives: Their evaluation as potential PDE 4B inhibitors possessing cytotoxic properties against cancer cells

The 2,2,4-trimethyl-1,2-dihydroquinolinyl substituted 1,2,3-triazole derivatives were designed as potential inhibitors of PDE4B. These compounds were synthesized via a multi-step sequence consisting of copper-catalyzed azide-alkyne cycloaddition (CuAAC) as a key step in aqueous media. The required alkynes were prepared from nimesulide via N-propargylation and then nitro group reduction followed by a CAN mediated modified Skraup reaction of the resulting amine. All the synthesized compounds showed PDE4B inhibitory properties in vitro at 30 μM with two compounds showing >50% inhibition that were supported by the in silico docking results of these compounds at the active site of PDE4B. Three of these PDE4 inhibitors showed promising cytotoxic properties against A549 human lung cancer cells in vitro with IC50 ～8-9 μM.

Novel molecules containing structural features of NSAIDs and 1,2,3-triazole ring: Design, synthesis and evaluation as potential cytotoxic agents

For the first time the template containing structural features of more than one NSAIDs and the 1,2,3-triazole ring was explored for the identification of potential cytotoxic agents. These new and complex molecules were predicted to be effective inhibitors

Synthesis and biological activities of carbonyl cobalt CORMs with selectively inhibiting cyclooxygenase-2

In this paper, three kinds of hybrid carbonyl cobalt CO-releasing molecules (CORMs), RCOOCH2C2H[Co2(CO)6] (R = NSAIDs-COOH, 1–11; R = celecoxib derivative-COOH, 15), RSO2(R’) CH2C2/su